Open Access Open Access  Restricted Access Subscription Access

GABA Agonist Baclofen Increases Beta cell Mass and C Peptide Level in Patients with Type 1 Diabetes

mahmoud younis

Abstract


Introduction: While diabetes continues to grow as a worldwide major health problem, its cause is obviously simple: β-cell failure. In type 1 diabetes (T1D), β cells are destroyed by autoimmunity, while in type 2 diabetes (T2D), there is a failure of β cells to compensate insulin resistance. Most cases of type 1 diabetes are due to autoimmunity, in the sense that patients often exhibit the features of an immunological contribution to disease (eg, autoantibodies or gene binding with genes that control immune responses). Nevertheless, many patients with type 1 diabetes don't have these features, resulting in proposed classifications for type 1A (autoimmune) diabetes. It is considered that renewal of normal beta cell mass and function could abolish diabetes. GABA is an essential neurotransmitter in the central nervous system. GABA is produced by pancreatic β-cells. It is elucidated that GABA takes part in preserving the β cell mass and in conserving β cells from death. Detects that long-range GABA treatment results in a considerable increase in c peptide levels. Materials and methods: two groups of type 1 diabetes patients had been monitored in a private clinic. In patients who were on baclofen tablets, there were significant differences between c peptide levels before and after treatment with p-value < 0.0001. In patients who were on insulin only, there were no significant differences between c peptide levels. Conclusion: GABA agonist baclofen may increase beta cell mass and c peptide levels in patients with type 1 diabetes.

Full Text:

PDF

References


Al-Hasani et al., 2013 K. Al-Hasani, A. Pfeifer, M. Courtney, N. Ben-Othman, E. Gjernes, A. Vieira, N.Druelle, F. Avolio, P. Ravassard, G. Leuckx, et al. Dev. Cell, 26 (2013), pp. 86-1001.

Leslie RD. Predicting adult-onset autoimmune diabetes: clarity from complexity. Diabetes. 2010; 59:330–31.

Mark A Atkinson, PhD, Prof, George S Eisenbarth, MD, Prof, and Aaron W Michels, MD.Type 1 diabetes, Lancet. 2014 Jan 4; 383(9911): 69–82.Published online 2013 Jul 26. doi: 10.1016/S0140-6736(13)60591-7.

Petitti DB, Klingensmith GJ, Bell RA, Andrews JS, Dabelea D, Imperatore G, Marcovina S, Pihoker C, Standiford D, Waitzfelder B, Mayer-Davis E. SEARCH for Diabetes in Youth Study Group: Glycemic control in youth with diabetes: The SEARCH for diabetes in Youth Study. J Pediatr. 2009; 155:668–672.

Eisenbarth GS. Update in type 1 diabetes. J Clin Endocrinol Metab. 2007; 92:2403–7.

Gianani R, Campbell-Thompson M, Sarkar SA, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia. 2010; 53:690–98.

Pipeleers D, et al. Restoring a functional beta-cell mass in diabetes. Diabetes Obes Metab. 2008; 10(suppl 4):54–62.

Meier JJ, et al. Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes. Diabetologia. 2006; 49:1838–1844.

Liese, A.D., R.B. D'Agostino, Jr., and R. Hamman, The burden of diabetes mellitus among US youth; prevalence estimates from the SEARCH for diabetes in youth study. Pediatrics, 2006. 118(4): p. 1510-18.

International Diabetes Federation. IDF diabetes atlas. 8th ed. Brussells: International Diabetes Federation; 2017.

Wang P, Fiaschi-Taesch NM, Vasavada RC, Scott DK, Garcia-Ocaña A, Stewart AF (2015) Advances and challenges in human beta cell proliferation for diabetes. Nat Rev Endocrinol 11:201–212.

Hering BJ, Clarke WR, Bridges ND et al (2016) Phase 3 trial or transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care 39:1230–1240.

Campbell-Thompson M, Fu A, Kaddis JS et al (2016) Insulitis and beta cell mass in the natural history of type 1 diabetes. Diabetes 65:719–731.

Cnop M, Hughes SJ, Igoillo-Esteve M et al (2010) The long lifespan and low turnover of human islet beta cells estimated by mathematical modeling of lipofuscin accumulation. Diabetologia 53:321–330.

Afelik S, Rovira M. Pancreatic β-cell regeneration: facultative or dedicated progenitors? Mol Cell Endocrinol. 2017; 445:85–94. doi: 10.1016/j.mce.2016.11.008.

Baeyens L, Lemper M, Leuckx G, De Groef S, Bonfanti P, Stangé G, et al. Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice. Nat Biotechnol. 2014; 32(1):76–83. doi: 10.1038/nbt.2747.

Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 2002; 129: 2447–2457.

Lee JC, Smith SB, Watada H et al. Regulation of the pancreatic pro‐endocrine gene neurogenin3. Diabetes 2001; 50: 928–936.

Lee CS, De Leon DD, Kaestner KH, Stoffers DA. Regeneration of pancreatic islets after partial pancreatectomy in mice does not involve the reactivation of neurogenin‐3. Diabetes 2006; 55: 269–272.

Murtaugh LC. Pancreas and beta‐cell development: from the actual to the possible. Development 2007; 134: 427–438.

Kittler JT, etal. Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: Implications for the efficacy of synaptic inhibition. Curr Opin Neurobiol. 2003; 13:341–347.

ian J, Zekzer D, etal. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone no obese diabetic mice. J Immunol. 2006; 176:2654–2661.

Adeghate E, Ponery AS. GABA in the endocrine pancreas: Cellular localization and function in normal and diabetic rats. Tissue Cell. 2002; 34:1–6.

Xu E, et al. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab. 2006; 3:47–58.

Brice, N.L., A. Varadi, S.J.H. Ashcroft, and E. Molnar. 2002. Metabotropic glutamate and GABAB receptors contribute to the modulation of glucose-stimulated insulin secretion in pancreatic β cells. Diabetologia. 45:242–252.

Kittler JT, Moss SJ. Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition. Curr Opin Neurobiol 2003; 13:341–347.

Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like micro vesicles suggests their role in GABA storage and secretion. EMBO J 1991; 10:1275–1284.

Dong H, Kumar M, Zhang Y, et al. Gamma-amino butyric acid up- and down regulates insulin secretion from beta cells in concert with changes in glucose concentration. Diabetologia 2006; 49:697–705.

Collombat, X. Xu, P. Ravassard, B. Sosa-Pineda, S. Dussaud, N. Billestrup, O.D. Madsen, P. Serup, H. Heimberg, A. Mansouri Cell, et al. 138 (2009), pp. 449-462.

Winnock F, et al. Correlation between GABA release from rat islet beta-cells and their metabolic state. Am J Physiol Endocrinol Metab. 2002; 282:E937–E942.

Adeghate and Ponery, 2002.E. Adeghate, A.S. Ponery .GABA in the endocrine pancreas: cellular localization and function in normal and diabetic rats

Tissue Cell, 34 (2002), pp. 1-6.

Soltani, H. Qiu, M. Aleksic, Y. Glinka, F. Zhao, R. Liu, Y. Li, N. Zhang et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc. Natl. Acad. Sci. USA, 108 (2011), pp. 11692-11697.

Tian J, Dang H, Chen Z, et al. γ-Amino butyric acid regulates both the survival and replication of human β-cells. Diabetes 2013; 62:3760–3765.

Ricordi C., Strom T. B. (2004). Clinical islet transplantation: advances and immunological challenges. Nat. Rev. Immunol. 4 259–268. 10.1038/nri1332.


Refbacks

  • There are currently no refbacks.